{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:53:36Z","timestamp":1787241216537,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:00:00Z","timestamp":1339459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The bone mass benefits of antiresorbers in postmenopausal osteoporosis are limited by the rapid coupling of decreasing bone resorption with bone formation. Wnt signaling is involved in this coupling process during treatment with bisphosphonates, whereas its role during treatment with the anti-receptor activator of NF-\u03baB ligand (RANKL) antibody denosumab is unknown. The study population includes patients participating in a placebo-controlled trial lasting 36 months: 19 women were on placebo and 24 on subcutaneous 60\u2009mg denosumab every 6 months. All measured parameters (serum C-terminal telopeptide of type I collagen [sCTX], serum bone alkaline phosphatase [bAP], Dickkopf-1 [DKK1], and sclerostin) remained unchanged during the observation period in the placebo group. sCTX and bAP were significantly suppressed by denosumab treatment over the entire follow-up. Denosumab treatment was associated with significant (p\u2009&amp;lt;\u20090.05) increases (28% to 32%) in serum sclerostin over the entire study follow-up. Serum DKK1 significantly decreased within the first 6 months with a trend for further continuous decreases, which reached statistical significance (p\u2009&amp;lt;\u20090.05) versus placebo group from the 18th month onward. The changes in DKK1 were significantly and positively related with the changes in sCTX and bAP and negatively with hip bone mineral density (BMD) changes. The changes in sclerostin were significantly and negatively related only with those of bAP. The changes in bone turnover markers associated with denosumab treatment of postmenopausal osteoporosis is associated with significant increase in sclerostin similar to those seen after long-term treatment with bisphosphonates and significant decrease in DKK1. This latter observation might explain the continuous increase over 5 years in BMD observed during treatment of postmenopausal osteoporosis with denosumab. \u00a9 2012 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.1681","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T12:03:39Z","timestamp":1339502619000},"page":"2259-2263","source":"Crossref","is-referenced-by-count":93,"title":["Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab"],"prefix":"10.1093","volume":"27","author":[{"given":"Davide","family":"Gatti","sequence":"first","affiliation":[{"name":"Unit of Rheumatology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fracassi","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Idolazzi","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Dartizio","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Povino","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvano","family":"Adami","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[{"name":"Unit of Rheumatology, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,6,12]]},"reference":[{"issue":"8","key":"2024020318304774700_bib1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"issue":"4","key":"2024020318304774700_bib2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/jbmr.5650100402","article-title":"Assessment of involutional bone loss: methodological and conceptual problems","volume":"10","author":"Adami","year":"1995","journal-title":"J Bone Miner Res."},{"key":"2024020318304774700_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molmed.2004.12.004","article-title":"Osteoclast-derived activity in the coupling of bone formation to resorption","volume":"11","author":"Martin","year":"2005","journal-title":"Trends Mol Med."},{"key":"2024020318304774700_bib4","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/en.2007-0270","article-title":"Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton","volume":"148","author":"Baron","year":"2007","journal-title":"Endocrinology."},{"key":"2024020318304774700_bib5","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1210\/jc.2005-2370","article-title":"Sclerostin and Wnt signaling\u2014the pathway to bone strength","volume":"90","author":"Ott","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2024020318304774700_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bone.2011.04.015","article-title":"Effects of estrogen on osteoprogenitor cells and cytokines\/bone-regulatory factors in postmenopausal women","volume":"49","author":"M\u00f6dder","year":"2011","journal-title":"Bone."},{"issue":"4","key":"2024020318304774700_bib7","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00198-011-1675-1","article-title":"Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women","volume":"23","author":"Chung","year":"2012","journal-title":"Osteoporos Int."},{"issue":"11","key":"2024020318304774700_bib8","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1210\/jc.2010-0720","article-title":"Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women","volume":"95","author":"Drake","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2024020318304774700_bib9","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2010-2552","article-title":"The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1","volume":"96","author":"Gatti","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2024020318304774700_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2024020318304774700_bib11","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest."},{"issue":"4","key":"2024020318304774700_bib12","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"issue":"2","key":"2024020318304774700_bib13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.maturitas.2010.02.008","article-title":"Treatment of osteoporosis with denosumab","volume":"66","author":"Lewiecki","year":"2010","journal-title":"Maturitas."},{"key":"2024020318304774700_bib14","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1359\/jbmr.060810","article-title":"Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity","volume":"21","author":"Ellies","year":"2006","journal-title":"J Bone Miner Res."},{"key":"2024020318304774700_bib15","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Sem\u00ebnov","year":"2005","journal-title":"J Biol Chem."},{"key":"2024020318304774700_bib16","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J."},{"key":"2024020318304774700_bib17","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J Biol Chem."},{"key":"2024020318304774700_bib18","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology."},{"issue":"11","key":"2024020318304774700_bib19","doi-asserted-by":"crossref","first-page":"E1848","DOI":"10.1210\/jc.2011-1534","article-title":"Acute decline in serum sclerostin in response to PTH infusion in healthy men","volume":"96","author":"Yu","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2024020318304774700_bib20","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/jc.2009-2283","article-title":"Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women","volume":"95","author":"Mirza","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318304774700_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jbmr.128","article-title":"Regulation of circulating sclerostin levels by sex steroids in women and in men","volume":"26","author":"M\u00f6dder","year":"2011","journal-title":"J Bone Miner Res."},{"key":"2024020318304774700_bib22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bone.2006.03.017","article-title":"Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia","volume":"39","author":"Li","year":"2006","journal-title":"Bone."},{"key":"2024020318304774700_bib23","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med."},{"key":"2024020318304774700_bib24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","article-title":"Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma","volume":"80","author":"Kaiser","year":"2008","journal-title":"Eur J Haematol."},{"key":"2024020318304774700_bib25","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1182\/blood-2011-04-351437","article-title":"Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1\u03b1 levels in patients with MGUS","volume":"118","author":"Ng","year":"2011","journal-title":"Blood."},{"key":"2024020318304774700_bib26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.autrev.2009.08.003","article-title":"The Wnt signaling pathway and rheumatoid arthritis","volume":"9","author":"Rabelo Fde","year":"2010","journal-title":"Autoimmun Rev."},{"key":"2024020318304774700_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/art.27231","article-title":"Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis","volume":"62","author":"Daoussis","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"3","key":"2024020318304774700_bib28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bone.2011.11.028","article-title":"Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin","volume":"50","author":"Gatti","year":"2012","journal-title":"Bone."},{"key":"2024020318304774700_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"N Engl J Med."},{"key":"2024020318304774700_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell."},{"issue":"Suppl 1","key":"2024020318304774700_bib31","article-title":"Five-year denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the freedom trial extension","volume":"22","author":"Papapoulos","year":"2011","journal-title":"Osteopor Int."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1681","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/27\/11\/2259\/56560303\/1681_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/27\/11\/2259\/56560303\/1681_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:47:07Z","timestamp":1710326827000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/27\/11\/2259-2263\/7598260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,12]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,6,12]]},"published-print":{"date-parts":[[2012,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1681","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717950268.793455525","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,11,1]]},"published":{"date-parts":[[2012,6,12]]}}}